Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF) (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Depreciation & Amortization (CF) data on record, last reported at $102000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 28.67% year-over-year to $102000.0; the TTM value through Dec 2025 reached $454000.0, down 43.74%, while the annual FY2025 figure was $454000.0, 43.74% down from the prior year.
  • Depreciation & Amortization (CF) reached $102000.0 in Q4 2025 per ACRS's latest filing, down from $110000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $288000.0 in Q1 2021 and bottomed at $102000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $192200.0, with a median of $197500.0 recorded in 2021.
  • The widest YoY moves for Depreciation & Amortization (CF): up 143.88% in 2021, down 67.68% in 2021.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $197000.0 in 2021, then fell by 3.55% to $190000.0 in 2022, then grew by 20.0% to $228000.0 in 2023, then tumbled by 37.28% to $143000.0 in 2024, then decreased by 28.67% to $102000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $102000.0 in Q4 2025, $110000.0 in Q3 2025, and $114000.0 in Q2 2025.